Abstract:Aim: Recombiant human telomerase reverse transcriptase (hTERT)-human IL-18(hIL18) was constructed to investigate its expression and biological function in eukaryotic cells. DCs transfected with hTERT-IL18 acquired stronger telomerase activity and were able to elicit an hTERT-specific cytotoxic T lymphocyte CTL response in vitro.Methods: hIL-18 gene fragment was amplified by Polymerase chain reaction (PCR) and TA cloned. The hIL18 gene was then subcloned into eukaryotic expression vector pcDNA3.1(+) containing human TERM via a linker. The sequence of gene fusion was confirmed using both restrictive enzyme digestion and DNA sequencer. The expression vector with gene fusion was transfected into 3T3 cell line with Lipofectamine 2000. ELISA, Western blot, immunofluorescence stain were performed to determine the expression properties of hTERT-hIL18 in 3T3 cells. Its biological effect on the anti-apoptosis was measured by Flow cytometry and its effect on INF-gamma expression was determined using ELISA. After preparation of dendritic cells, hTERT-hIL18, hTERT, hIL-18 expression vectors were transfected into DCs respectively by electroporation to generate hTERT-specific DCs lines. The peripheral blood mononuclear cells PBMCs were stimulated with different DCs lines to create specific CTL. The response of target cell (leukemia cell line-K562 cell) to hTERT-specific CTL was evaluated by LDH release assay.Results: The human IL-18 gene fragment was amplified from the human mononuclear cells and was inserted into pcDNA3.1(+)/hTERT vector successfully. The correct sequence was proved by both restrictive enzyme digestion and sequencing. The correct open reading frame was also verified. Fusion protein of hTERT-hIL18 was effectively expressed in eukaryotic cells, which was detected by both Western-blotting and immunofluorescence stain. The expressed recombinant fusion protein induced similar levels of INF-gamma to that of native IL-18 protein. FCM assay showed that the transfected fusion protein inhibited the apoptosis, which was consistent with the effects of hTERT as a universal tumor associated antigen. CTL assay shows that hTERT-hIL18 and hTERT gene-transfected DCs stimulated T-cell responses that recognized and lysed tumor target cells of high hTERT expression, whereas DCs transfected with hIL-18 gene didn't induced the response of tumor targets lyses.Conclusion: The Recombinant hTERT-hIL18 fusion protein had both biological activity of hTERT and hIL-18, indicating that this rationally designed protein can be further developed as novel tumor therapeutics. DCs transfected with hTERT-IL18 gene were capable of eliciting a stronger hTERT-specific CTL response in vitro.

Fusion Protein of ATPase Domain of Hsc70 with TRP2 Acting As a Tumor Vaccine Against B16 Melanoma.

Fusion Proteins of Hsp70 with Tumor-Associated Antigen Acting As A Potent Tumor Vaccine and the C-Terminal Peptide-Binding Domain of Hsp70 Being Essential in Inducing Antigen-Independent Anti-Tumor Response in Vivo

The Fusion Protein of Hsp65 with Tandem Repeats of Beta-Hcg Acting As A Potent Tumor Vaccine in Suppressing Hepatocarcinoma

Antitumor therapeutic effect induced by intestine- carcinoma cells vaccine expressing membrane- bound heat shock protein 70

Heat Shock Fusion Protein Induces Both Specific And Nonspecific Anti-Tumor Immunity

Recombinant heat shock protein 70 functional peptide and alpha-fetoprotein epitope peptide vaccine elicits specific anti-tumor immunity

Prokaryotic Expression, Purification of HSP65-MUC1 VNTR2 Fusion Protein and Primary Research on Its Tumoricidal Effect

Enhanced antitumor immunity of nanoliposome-encapsulated heat shock protein 70 peptide complex derived from dendritic tumor fusion cells

A 14-mer Peptide from HSP70 Protein is the Critical Epitope Which Enhances NK Activity Against Tumor Cells in vivo

Recent Advances in Heat Shock Protein-Based Cancer Vaccines

Vaccination with the Repeat Β-Hcg C-terminal Peptide Carried by Heat Shock Protein-65 (HSP65) for Inducing Antitumor Effects

Development Of A Recombinant Hsp110-Her-2/Neu Vaccine Using The Chaperoning Properties Of Hsp110

Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy.

Construction of Expression Vector of Htert- Hil18 Fusion Gene and Induction of Cytotoxic T Lymphocyte Response Against Htert.

Heat Shock Protein 70/MAGE-3 Fusion Protein Vaccine Can Enhance Cellular and Humoral Immune Responses to MAGE-3 in Vivo.

A Modified HLA-A*0201-restricted CTL Epitope from Human Oncoprotein (hpebp4) Induces More Efficient Antitumor Responses

A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis.

Purification of heat shock protein 70-associated tumor peptides and its antitumor immunity on hepatoma in mice

Immunization of Protein HPV16 E7 in Fusion with Mouse HSP70 Inhibits the Growth of TC-1 Cells in Tumor Bearing Mice.

Dendritic-Tumor Fusion Cells Derived Heat Shock Protein70-Peptide Complex Has Enhanced Immunogenicity

Vaccination with B16 tumor cell lysate plus recombinant Mycobacterium tuberculosis Hsp70 induces antimelanoma effect in mice.